Triple,,,, Members do that all the time on Threads,,just about all threads. It's called thread drift. Thats what potheads do. No big deal brother. We are all friends here.
Thats all fine and good but even his statement is false at this time. A committee recommended to the FDA that the oral versions of phenylephrine are not effective. Nothing has been removed yet and the FDA does not even have to abide by the recommendations of the committee.
Speculation at best but like i said....The hard evidence says otherwise.
A 2007 meta-analysis concluded that the evidence for its effectiveness is insufficient,
[16] though another meta-analysis published shortly thereafter by researchers from
GlaxoSmithKline found the standard 10-mg dose to be more effective than a placebo; however, the fact that GSK markets many products containing phenylephrine has raised some speculation regarding selective publishing and other controversial techniques.
[17] A 2007 study by
Wyeth Consumer Healthcare notes that 7 studies available in 1976 support the efficacy of phenylephrine at a 10 mg dosage.
[18] The
Food and Drug Administration withdrew the indication "for the temporary relief of nasal congestion associated with sinusitis" in 2007.
[2]
Two studies published in 2009, examined the effects of phenylephrine on symptoms of
allergic rhinitis by exposing people to pollen in a controlled, indoor environment. Neither study was able to distinguish between the effects of phenylephrine or a placebo. Pseudoephedrine and
loratadine–
montelukast therapy were found to be significantly more effective than both phenylephrine and placebo.
[13][14]
Pseudoephedrine was previously much more commonly available in the United States, however, provisions of the
Combat Methamphetamine Epidemic Act of 2005 placed restrictions on the sale of pseudoephedrine products to prevent the
clandestine manufacture of methamphetamine. Since 2004, phenylephrine has been increasingly marketed as a substitute for pseudoephedrine; some manufacturers have changed the active ingredients of products to avoid the restrictions on sales.
[19] Phenylephrine has been off-patent for some time, and many generic brands are available.[
citation needed]
On 12 September 2023, an independent advisory committee to the FDA unanimously agreed that there is insufficient evidence showing that "orally administered phenylephrine is effective as a nasal decongestant". The committee also unanimously believed that this does not need further study. The FDA responded to the committee, stating it would take its advice under advisement